open access

Vol 11, No 5 (2022)
Research paper
Submitted: 2021-04-28
Accepted: 2021-09-28
Published online: 2022-09-30
Get Citation

Long Term Safety and Efficacy of Saroglitazar in Indian Patients with Diabetic Dyslipidemia and Very High Triglyceride Levels: Real World Evidence

Arjun Baidya1
DOI: 10.5603/DK.a2022.0039
·
Clinical Diabetology 2022;11(5):316-320.
Affiliations
  1. Department of Endocrinology and Metabolism, Nil Ratan Sircar Medical College, Kolkata, India

open access

Vol 11, No 5 (2022)
Original articles
Submitted: 2021-04-28
Accepted: 2021-09-28
Published online: 2022-09-30

Abstract

Objective: Diabetes and diabetic dyslipidemia with high triglycerides (TGs) are commonly associated. Saroglitazar is the first dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. The objective of this observational study was to assess the long-term safety and efficacy of saroglitazar in patients with diabetic dyslipidemia with very high triglycerides (> 500 mg/dL). Materials and methods: This was a single-center, retrospective observational study which was conducted among 150 patients with type 2 diabetes who had diabetic dyslipidemia with hypertriglyceridemia (> 500 mg/dL at baseline). All patients were on saroglitazar 4 mg once daily and all had complete follow-up data. At baseline, all patients were on stable doses of antidiabetic and statin therapy. Results: Significant reduction of TG and LDL-cholesterol was observed from baseline to 12th week: from 669.93 ± 81.22 to 268.72 ± 82.32 mg/dL and from 167.68 ± 10.881 to 118.88 ± 12.16 mg/dL (p < 0.0001 and < 0.001), respectively. The mean HbA1c was reduced from 8.02 ± 0.3 to 7.71 ± 0.5% (< 0.001). This reduction in lipid and glycemic parameters continued till 52th week. At 52 weeks mean TG, LDL-cholesterol and HbA1c were reduced to 221.51 ± 61.81 mg/dL, 118.88 ± 12.16 mg/dL and 7.12 ± 0.2 % (p <0.001 for all). No major adverse event was reported during the study period. Creatine phosphokinase (CPK), liver enzymes and creatinine did not alter significantly. Conclusions: Long term use of saroglitazar leads to significant improvement in both glycemic and lipid parameters in patients with diabetic dyslipidemia with very high triglycerides (>500 mg/dl) and initially not controlled by statins alone. Therefore, to fulfil the unmet need, long-term use of saroglitazar could be an effective, well tolerated and safe option.

Abstract

Objective: Diabetes and diabetic dyslipidemia with high triglycerides (TGs) are commonly associated. Saroglitazar is the first dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. The objective of this observational study was to assess the long-term safety and efficacy of saroglitazar in patients with diabetic dyslipidemia with very high triglycerides (> 500 mg/dL). Materials and methods: This was a single-center, retrospective observational study which was conducted among 150 patients with type 2 diabetes who had diabetic dyslipidemia with hypertriglyceridemia (> 500 mg/dL at baseline). All patients were on saroglitazar 4 mg once daily and all had complete follow-up data. At baseline, all patients were on stable doses of antidiabetic and statin therapy. Results: Significant reduction of TG and LDL-cholesterol was observed from baseline to 12th week: from 669.93 ± 81.22 to 268.72 ± 82.32 mg/dL and from 167.68 ± 10.881 to 118.88 ± 12.16 mg/dL (p < 0.0001 and < 0.001), respectively. The mean HbA1c was reduced from 8.02 ± 0.3 to 7.71 ± 0.5% (< 0.001). This reduction in lipid and glycemic parameters continued till 52th week. At 52 weeks mean TG, LDL-cholesterol and HbA1c were reduced to 221.51 ± 61.81 mg/dL, 118.88 ± 12.16 mg/dL and 7.12 ± 0.2 % (p <0.001 for all). No major adverse event was reported during the study period. Creatine phosphokinase (CPK), liver enzymes and creatinine did not alter significantly. Conclusions: Long term use of saroglitazar leads to significant improvement in both glycemic and lipid parameters in patients with diabetic dyslipidemia with very high triglycerides (>500 mg/dl) and initially not controlled by statins alone. Therefore, to fulfil the unmet need, long-term use of saroglitazar could be an effective, well tolerated and safe option.

Get Citation

Keywords

saroglitazar, high triglyceride, type 2 diabetes, dyslipidemia

About this article
Title

Long Term Safety and Efficacy of Saroglitazar in Indian Patients with Diabetic Dyslipidemia and Very High Triglyceride Levels: Real World Evidence

Journal

Clinical Diabetology

Issue

Vol 11, No 5 (2022)

Article type

Research paper

Pages

316-320

Published online

2022-09-30

Page views

120

Article views/downloads

55

DOI

10.5603/DK.a2022.0039

Bibliographic record

Clinical Diabetology 2022;11(5):316-320.

Keywords

saroglitazar
high triglyceride
type 2 diabetes
dyslipidemia

Authors

Arjun Baidya

References (20)
  1. Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care. 2004; 10(2): 163–170.
  2. Mooradian AD, Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009; 5(3): 150–159.
  3. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids. 2010; 45(10): 907–914.
  4. World Health Organization. (‎2011)‎. Global status report on noncommunicable diseases 2010. World Health Organization. https://apps.who.int/iris/handle/10665/44579 (27.04.2021).
  5. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004; 364(9438): 937–952.
  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001; 285(19): 2486–2497.
  7. Athyros VG, Giouleme OI, Nikolaidis NL, et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol. 2002; 34(4): 472–475.
  8. DiMagno EP, Chari S. Acute ancreatitis. In: Feldman M, Friedman LS, Sleisenger LH. ed. Sleisenger & Fordtran’s gastrointestinal and liver disease. W B Saunders, St. Louis (MO) 2002: 913–942.
  9. Chatterjee S, Majumder A, Ray S. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes. Sci Rep. 2015; 5: 7706.
  10. Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014; 16(2): 63–71.
  11. Pai V, Paneerselvam A, Mukhopadhyay S, et al. A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014; 8(1): 132–141.
  12. Kaul U, Arambam P, Kachru R, et al. A Prospective, Multicentre, Single Arm Clinical Study to Evaluate the Effect of saroglitazar on NonHigh-Density Lipoprotein Cholesterol in Patients with Diabetic Dyslipidemia Inadequately Controlled with Diet, Exercise, and Statin-The GLIDDER Study. J Diabetes Metab. 2019; 10: 2(819): 1–8.
  13. Joshi SR, Anjana RM, Deepa M, et al. ICMR-INDIAB Collaborative Study Group. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014; 9(5): e96808.
  14. 20th Annual Convention of the American Association of Physicians of Indian Origin Clinical Implications: Dyslipidemia in the Asian Indian Population June 29, 2002. https://southasianheartcenter.org/docs/AAPImonograph.pdf (27.04.2021).
  15. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-offunction mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014; 371(1): 32–41.
  16. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384(9943): 626–635.
  17. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2019; 43(Supplement_1): S111–S134.
  18. Shetty SR, Kumar S, Mathur RP, et al. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. Indian Heart J. 2015; 67(1): 23–26.
  19. Joshi S, Vadgama J, Mody P, et al. Abstract #1224 Saroglitazar in the Treatment of Severe Hypertriglyceridemia in Patients with Type 2 Diabetes. Endocrine Practice. 2018; 24(supp. 1): 318.
  20. Chatterjee S. Obser vational Study of Saroglitazar on Metabolic Parameters in Indian Patients with Diabetic Dyslipidaemia – A Fifty Eight Weeks of Clinical Experience. Diabetes & Obesity International Journal. 2018; 3(2).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl